Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
revenue guidance of US$800 million to US$825 million, and reported 2025 results showing revenue rising to US$944 million with a full-year net loss of US$381 million. The company also highlighted growing commercial traction for TRYNGOLZA and DAWNZERA and new DAWNZERA data in hereditary angioedema, underlining its shift into a broader commercial-stage rare disease and cardiometabolic franchise. We'll now examine how olezarsen's FDA Priority Review and Ionis's expanding commercial footprint influence the company's existing investment narrative. Find 46 companies with promising cash flow potential yet trading below their fair value Ionis Pharmaceuticals Investment Narrative Recap To own Ionis, you need to believe that RNA-targeted drugs can scale from rare diseases into larger cardiometabolic markets while the company manages pricing pressure and continued losses. The olezarsen Priority Review is now the clear near term catalyst, focusing attention on the June 30, 2026 PDUFA dat
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals (IONS) had its price target raised by Leerink Partners from $102.00 to $104.00. They now have an "outperform" rating on the stock.MarketBeat
- Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals (IONS) had its price target raised by Piper Sandler from $87.00 to $100.00. They now have an "overweight" rating on the stock.MarketBeat
- Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual MeetingBusiness Wire
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- IONS's page on the SEC website